Company intelligence / Profile preview
Santo Therapeutics
Chinasantobiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Santo Therapeutics is developing next-generation lentiviral vector-based gene therapies targeting rare diseases and cancers. Their approach focuses on reprogramming cellular self-protection mechanisms to control tumor growth, aiming for one-time treatments that deliver lifelong cures. The company’s technology platforms emphasize safety, precision targeting, and scalable manufacturing.[1]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Lentiviral vectors (LV)Gene therapyGene editing technologies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Santo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Santo Therapeutics.